Lessons from dermatology about inflammatory responses in Covid‐19

Reviews in Medical Virology - Tập 30 Số 5 - 2020
Paulo Ricardo Criado1, Carla Pagliari2, Francisca Regina Oliveira Carneiro3, Juarez Antônio Simões Quaresma3
1Dermatology Department Centro Universitário Saúde ABC Santo André Brazil
2Pathology Department, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
3Center of Biological and Health Sciences State University of Pará Belém Brazil

Tóm tắt

SummaryThe SARS‐Cov‐2 is a single‐stranded RNA virus composed of 16 non‐structural proteins (NSP 1‐16) with specific roles in the replication of coronaviruses. NSP3 has the property to block host innate immune response and to promote cytokine expression. NSP5 can inhibit interferon (IFN) signalling and NSP16 prevents MAD5 recognition, depressing the innate immunity. Dendritic cells, monocytes, and macrophages are the first cell lineage against viruses' infections. The IFN type I is the danger signal for the human body during this clinical setting. Protective immune responses to viral infection are initiated by innate immune sensors that survey extracellular and intracellular space for foreign nucleic acids. In Covid‐19 the pathogenesis is not yet fully understood, but viral and host factors seem to play a key role. Important points in severe Covid‐19 are characterized by an upregulated innate immune response, hypercoagulopathy state, pulmonary tissue damage, neurological and/or gastrointestinal tract involvement, and fatal outcome in severe cases of macrophage activation syndrome, which produce a ‘cytokine storm’. These systemic conditions share polymorphous cutaneous lesions where innate immune system is involved in the histopathological findings with acute respiratory distress syndrome, hypercoagulability, hyperferritinemia, increased serum levels of D‐dimer, lactic dehydrogenase, reactive‐C‐protein and serum A amyloid. It is described that several polymorphous cutaneous lesions similar to erythema pernio, urticarial rashes, diffuse or disseminated erythema, livedo racemosa, blue toe syndrome, retiform purpura, vesicles lesions, and purpuric exanthema or exanthema with clinical aspects of symmetrical drug‐related intertriginous and flexural exanthema. This review describes the complexity of Covid‐19, its pathophysiological and clinical aspects.

Từ khóa


Tài liệu tham khảo

10.1007/s12098-020-03263-6

Coronavirus Resource Center of the John Hopkins University. Disposable onhttps://coronavirus.jhu.edu/map.html

10.1111/jdv.16387

10.1080/23744235.2020.1747634

10.1111/all.14289

Zhang Y, 2020, Clinical and coagulation characteristics of 7 patients with critical Covid‐2019 pneumonia and acro‐ischemia, Zhonghua Xue Ye Xue Za Zhi, 41, E006

10.1080/22221751.2020.1741327

Azzotta F, Acute acro‐ischemia in the child at the time of Covid‐19, Eur J Ped Dermatol

10.1111/dth.13329

10.1111/dth.13310

10.1016/j.jaad.2020.03.012

Tao J., 2020, Emergency management for preventing and controlling nosocomial infection of the 2019 novel coronavirus: implications for the dermatology department, British Journal of Dermatology

10.1111/jdv.16412

10.1111/jdv.16391

10.1111/ajd.13295

10.1016/j.jaad.2020.03.046

10.1111/dth.13357

10.1016/j.jaad.2020.03.014

10.1111/jdv.16411

10.1056/NEJMp2006141

10.1016/j.semcancer.2004.06.009

10.1002/jmv.25681

Asian Pacific Journal of Allergy and Immunology 2020 Immune responses in COVID‐19 and potential vaccines: Lessons learned from SARS and MERS epidemic

10.1146/annurev-immunol-051116-052331

10.1002/jmv.25685

Ferro F, 2020, Covid‐19: the new challenge for rheumatologists, Clin Exp Rheumatol, 38, 175, 10.55563/clinexprheumatol/r3k9l6

10.55563/clinexprheumatol/xcdary

10.1002/path.1570

10.1016/j.ijcard.2018.10.002

10.1016/j.biochi.2017.07.016

10.1016/j.jmii.2020.03.022

10.15252/embj.20105114

10.1128/JVI.02202-13

10.1128/JVI.01542-10

10.1016/j.cell.2020.02.052

10.1016/j.jaci.2012.05.023

10.1038/nm1462

10.1111/j.1365-2222.2008.02954.x

10.4049/jimmunol.0901194

10.1111/1523-1747.ep12324502

10.1186/s12931-017-0630-x

10.1016/j.chest.2020.03.032

10.1016/S2213-2600(20)30076-X

10.1164/rccm.200909-1420OC

10.1016/j.jiph.2019.05.017

10.1056/NEJMc2007575

10.1053/sarh.2002.28303

10.1016/S0140-6736(06)68474-2

10.1111/j.1538-7836.2011.04340.x

Tan CW, 2020, Critically ill Covid‐19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability, Am J Hematol, 10

Yin S, 2020, Difference of coagulation features between severe pneumonia induced by SARS‐CoV2 and non‐SARS‐CoV2, J Thromb Thrombolysis, 1

10.1111/jth.14817

10.1053/jhep.2001.26522

Solaimanzadeh I., 2020, Acetazolamide, nifedipine and phosphodiesterase inhibitors: Rationale for their utilization as adjunctive countermeasures in the treatment of coronavirus disease 2019 (Covid‐19), Cureus, 12, e7343

10.1093/eurheartj/ehx321

10.3389/fimmu.2019.02734

10.3389/fimmu.2019.01059

10.3389/fimmu.2017.00344

10.1016/j.jaad.2015.04.063

10.1007/s00296-011-2025-5

10.1111/cup.13466

10.1182/asheducation-2018.1.313

10.1016/j.jaad.2013.07.019

10.1177/1534734614535407

10.1111/dth.12225

10.1111/cup.13043

10.1001/archderm.134.4.447

10.1016/j.jaad.2011.07.021

10.1016/j.mehy.2015.08.009

10.1111/ijd.13997

Iqbal AM, 2020, StatPearls [Internet]

10.1007/s11239-011-0556-y

Yong AA, 2012, Livedoid vasculopathy and its association with factor V Leiden mutation, Singapore Med J, 53, e258

Bermejo Martin JF, 2003, Pentoxifylline and severe acute respiratory syndrome (SARS): a drug to be considered, Med Sci Monit, 9, SR29

10.1177/095632020601700505

10.1111/j.1468-3083.2010.03646.x

10.3390/medicines6030080

10.1111/jth.14821

10.3390/jcm8101747

Hafner C, 2005, Lipodermatosclerosis: successful treatment with danazol, Acta Derm Venereol, 85, 365

10.4103/0378-6323.164217

10.1111/j.1365-2133.2005.06843.x

10.1007/s00134-006-0367-3

10.4103/0378-6323.183635

Gan EY, 2012, A ten‐year retrospective study on livedo vasculopathy in Asian patients, Ann Acad Med Singapore, 41, 400, 10.47102/annals-acadmedsg.V41N9p400

10.1093/jac/dkv018

10.1016/j.ijantimicag.2020.105960

10.3399/bjgpopen20X101069

10.2340/00015555-2416

10.1111/jth.14828

10.1016/j.jaad.2014.05.039

10.1111/dth.12233

10.1111/dth.13229

10.1093/ofid/ofaa102

Leclerc AF, 2000, Livedoid vasculitis: about five cases treated with cyclosporin, Nouvelles Dermatologiques, 19, 356

10.1160/TH07-01-0037

10.1128/MCB.19.3.2032

Gao Y, 2020, Efficacy of an anti‐TNF‐alpha agent in refractory livedoid vasculopathy: a retrospective analysis, J Dermatolog Treat, 9, 1

Maranhão RC, 2014, Lipoprotein (a): structure, pathophysiology and clinical implications, Arq Bras Cardiol, 103, 76

10.1017/S1047951105000454

10.1152/physrev.00013.2020

10.1016/j.jaad.2020.04.032

Wenzhong liu, 2020, ChemRxiv

10.3899/jrheum.200334

10.1016/j.autrev.2020.102537

Thông tin
Thông tin xuất bản

Reviews in Medical Virology

Tập 30 Số 5

Thông tin tác giả